BioInvent International AB (publ) (STO:BINV)
Sweden
· Delayed Price · Currency is SEK 28.85
-0.20 (-0.69%)
At close: Dec 5, 2025
STO:BINV Revenue
BioInvent International AB had revenue of 3.32M SEK in the quarter ending September 30, 2025, a decrease of -73.98%. This brings the company's revenue in the last twelve months to 244.85M, up 533.73% year-over-year. In the year 2024, BioInvent International AB had annual revenue of 44.69M, down -37.47%.
Revenue (ttm)
244.85M
Revenue Growth
+533.73%
P/S Ratio
7.75
Revenue / Employee
1.97M
Employees
114
Market Cap
1.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.69M | -26.78M | -37.47% |
| Dec 31, 2023 | 71.46M | -254.67M | -78.09% |
| Dec 31, 2022 | 326.13M | 306.74M | 1,582.45% |
| Dec 31, 2021 | 19.38M | -127.99M | -86.85% |
| Dec 31, 2020 | 147.37M | 53.63M | 57.21% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 27.85B |
| Getinge AB | 35.85B |
| Sectra AB | 3.37B |
| Camurus AB | 2.35B |
| Medicover AB | 25.67B |
| Asker Healthcare Group AB | 16.41B |
| BioArctic AB | 1.92B |
| AddLife AB | 10.53B |
BioInvent International AB News
- 5 weeks ago - BioInvent International AB (FRA:BIX0) Q3 2025 Earnings Call Highlights: Strategic Focus Amidst ... - GuruFocus
- 5 weeks ago - Q3 2025 BioInvent International AB Earnings Call Transcript - GuruFocus
- 5 weeks ago - BioInvent International AB (publ) 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 5 weeks ago - BioInvent International AB (publ) (BOVNF) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Transgene and BioInvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments - Benzinga